Investigating a new antiviral treatment for enterovirus D68 in children
Drug target validation of the enterovirus D68 2A protease
This study is looking for new ways to help kids who get sick from a virus called enterovirus D68, which can cause serious breathing problems and other health issues, by finding parts of the virus that we can target with medicines, including a possible use of an existing drug to help treat them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10895546 on NIH RePORTER |
What this research studies
This research focuses on enterovirus D68 (EV-D68), a virus that can cause severe respiratory illness and neurological complications in children. The study aims to identify new viral proteins that can serve as targets for antiviral drugs and to develop chemical probes to validate these targets. Researchers are particularly interested in the 2A protease of EV-D68, which has shown potential for inhibition by an existing FDA-approved drug, telaprevir. By exploring this approach, the research seeks to provide a safe and effective treatment option for children affected by EV-D68.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who are at risk of or affected by enterovirus D68 infections.
Not a fit: Patients who are older than 11 years or those not infected with enterovirus D68 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral treatments for children suffering from EV-D68 infections.
How similar studies have performed: Previous research has shown promise in repurposing existing antiviral drugs for similar viral infections, indicating potential success for this approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Wang, Jun — Rutgers Biomedical and Health Sciences
- Study coordinator: Wang, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.